_ibrutinib-combined-with-obinutuzumab-and-venetoclax-for-treatment-naive-older-patients-with-cll.jpg "Ibrutinib Combined With Obinutuzumab and Venetoclax for Treatment-Naive Older Patients With CLL from obinutuzumab and venetoclax in cll Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 2 min 48 sec
✓ Published: 19-Jun-2023
✓ Published: 19-Jun-2023
Description:
Jennifer Ann Woyach, MD, shares data on ibrutinib combined with obinutuzumab and venetoclax vs ibrutinib plus obinutuzumab for the frontline treatment of older patients with CLL in the setting of the COVID-19 pandemic.
Jennifer Ann Woyach, MD, shares data on ibrutinib combined with obinutuzumab and venetoclax vs ibrutinib plus obinutuzumab for the frontline treatment of older patients with CLL in the setting of the COVID-19 pandemic.
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_venetoclax-and-obinutuzumab-for-cll.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_cll14-venetoclax-plus-obinutuzumab-in-untreated-cll.webp "Dr Othman Al-Sawaf speaks to ecancer about the four-year follow-up of the CLL14 trial looking at venetoclax and obinutuzumab in untreated chronic lymphocyte leukaemia. nnDr Al Sawaf explains that venetoclax plus obinutuzumab has been established as a fixed-duration treatment regimen for patients with chronic lymphocytic leukaemia. In the CLL14 trial, the long-term efficacy after treatment cessation of the combination of venetoclax plus obinutuzumab with chlorambucil plus obinutuzumab was compare")
_six-year-update-from-cll14-fixed-duration-venetoclax-obinutuzumab-for-previously-untreated-cll.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
⏲ 1 minute 43 seconds 👁 88
_6-year-results-of-cll14-venetoclax-obinutuzumab-for-previously-untreated-cll.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
⏲ 5 minutes 59 seconds 👁 828
_majic-venetoclax-with-acalabrutinib-or-obinutuzumab-in-cll.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_venetoclax-obinutuzumab-impact-on-cll-management.webp "OncLiveTV")
_amy-pierre-anp-bc-on-cll-in-older-patients-the-alliance-trial-on-ibrutinib-obinutuzumab-and-venetoclax.webp "Amy Pierre, ANP-BC, on CLL in Older Patients: The Alliance Trial on Ibrutinib, Obinutuzumab, and Venetoclax from obinutuzumab and venetoclax in cll")
⏲ 1 min 41 sec ✓ 09-Dec-2019
_cll14-venetoclax-plus-obinutuzumab-for-cll.webp "VJHemOnc – Video Journal of Hematology u0026 HemOnc")
_venetoclax-and-obinutuzumab-for-cll.jpg)
_cll14-venetoclax-plus-obinutuzumab-in-untreated-cll.jpg)
_six-year-update-from-cll14-fixed-duration-venetoclax-obinutuzumab-for-previously-untreated-cll.jpg)
_6-year-results-of-cll14-venetoclax-obinutuzumab-for-previously-untreated-cll.jpg)
_majic-venetoclax-with-acalabrutinib-or-obinutuzumab-in-cll.jpg)
_venetoclax-obinutuzumab-impact-on-cll-management.jpg)
_amy-pierre-anp-bc-on-cll-in-older-patients-the-alliance-trial-on-ibrutinib-obinutuzumab-and-venetoclax.jpg)
_cll14-venetoclax-plus-obinutuzumab-for-cll.jpg)
![[+]](/images/menu.gif){kind=small}